Marksans Pharma Limited

NSEI:MARKSANS Stock Report

Market Cap: ₹109.3b

Marksans Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Mark Saldanha

Chief executive officer

₹68.9m

Total compensation

CEO salary percentage69.7%
CEO tenure9.3yrs
CEO ownership43.8%
Management average tenure13.2yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 01
Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Nov 27
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17
Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16
This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01
Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14
Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19
Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

CEO Compensation Analysis

How has Mark Saldanha's remuneration changed compared to Marksans Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹3b

Jun 30 2024n/an/a

₹3b

Mar 31 2024₹69m₹48m

₹3b

Dec 31 2023n/an/a

₹3b

Sep 30 2023n/an/a

₹3b

Jun 30 2023n/an/a

₹3b

Mar 31 2023₹52m₹48m

₹3b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹2b

Jun 30 2022n/an/a

₹2b

Mar 31 2022₹38m₹35m

₹2b

Dec 31 2021n/an/a

₹2b

Sep 30 2021n/an/a

₹2b

Jun 30 2021n/an/a

₹3b

Mar 31 2021₹10m₹10m

₹2b

Dec 31 2020n/an/a

₹2b

Sep 30 2020n/an/a

₹2b

Jun 30 2020n/an/a

₹1b

Mar 31 2020₹10m₹10m

₹1b

Dec 31 2019n/an/a

₹879m

Sep 30 2019n/an/a

₹834m

Jun 30 2019n/an/a

₹780m

Mar 31 2019₹10m₹10m

₹804m

Dec 31 2018n/an/a

₹666m

Sep 30 2018n/an/a

₹582m

Jun 30 2018n/an/a

₹463m

Mar 31 2018₹12m₹10m

₹358m

Compensation vs Market: Mark's total compensation ($USD794.54K) is above average for companies of similar size in the Indian market ($USD493.22K).

Compensation vs Earnings: Mark's compensation has increased by more than 20% in the past year.

CEO

Mark Saldanha (52 yo)

9.3yrs

Tenure

₹68,857,053

Compensation

Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Saldanha
Non-Independent Executive Chairman & MDno data₹68.86m43.8%
₹ 47.9b
Jitendra Sharma
Chief Financial Officer22.4yrs₹12.84mno data
Vishal Bhargava
Director Operationsno data₹5.80mno data
Harshavardhan Panigrahi
Company Secretary16yrs₹2.84mno data
Sandra Saldanha
Whole-Time Executive Non Independent Director10.4yrs₹7.07m0.073%
₹ 79.7m
Varddhman Jain
Whole-Time Executive Non Independent Director6.1yrs₹18.75mno data
Sunil Rane
Senior Vice President of QCno data₹10.61mno data
David Mohammed
Managing Director of Australia Operationsno datano datano data
Sathish Kumar
Managing Director of UK Operationsno datano datano data
Anjani Kumar
Chief Operating Officer of US Operationsno data₹10.29mno data
Varddhaman Jain
no datano datano data

13.2yrs

Average Tenure

54yo

Average Age

Experienced Management: MARKSANS's management team is seasoned and experienced (13.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Saldanha
Non-Independent Executive Chairman & MD9.3yrs₹68.86m43.8%
₹ 47.9b
Sandra Saldanha
Whole-Time Executive Non Independent Director10.4yrs₹7.07m0.073%
₹ 79.7m
Varddhman Jain
Whole-Time Executive Non Independent Director6.1yrs₹18.75mno data
Varddhaman Jain
6.1yrsno datano data
Sunny Sharma
Non-Executive & Non-Independent Director3.5yrsno datano data
Abhinna Mohanty
Non-Executive & Independent Director5.6yrs₹15.00kno data
Digant Parikh
Non-Executive Independent Director6.9yrs₹400.00kno data
Shailaja Vardhan
Non-Executive & Independent Director1.8yrs₹300.00kno data
Seetharama Buddharaju
Non-Executive & Independent Director13.3yrs₹25.00kno data

6.1yrs

Average Tenure

53.5yo

Average Age

Experienced Board: MARKSANS's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 20:26
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Marksans Pharma Limited is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ranjit KapadiaCentrum Broking Limited
Deepika MurarkaChoice Equity Broking Private Limited
Nitin AgarwalDAM Capital Advisors